コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 range of gram-positive pathogens, including methicillin-resistant Staphylococcus aureus.
2 ded antibiotic that is highly potent against methicillin-resistant Staphylococcus aureus.
3 ICUs are a major reservoir of methicillin-resistant Staphylococcus aureus.
4 sitive infections, including those caused by methicillin-resistant Staphylococcus aureus.
5 obacteriaceae, and methicillin-sensitive and methicillin-resistant Staphylococcus aureus.
6 ogens, including Gram-positive pathogens and methicillin-resistant Staphylococcus aureus.
7 cluding vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus.
8 sion for intravenous antibiotic treatment of methicillin-resistant Staphylococcus aureus.
9 against drug-resistant pathogens, including methicillin-resistant Staphylococcus aureus.
10 ial infections, particularly those caused by methicillin-resistant Staphylococcus aureus.
11 acting healthcare-associated infections like methicillin-resistant Staphylococcus aureus.
13 ncomycin-resistant Enterococcus faecium [0], methicillin-resistant Staphylococcus aureus [5], extende
14 oncern, especially regarding the outbreak of methicillin-resistant Staphylococcus aureus, a common ca
16 atient with two episodes of cutaneous USA300 methicillin-resistant Staphylococcus aureus abscess.
18 show no significant toxicity to the bacteria methicillin-resistant Staphylococcus aureus and Escheric
19 y against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and isolates
20 resulted in 3 log and 2.6 log reductions of methicillin-resistant Staphylococcus aureus and Pseudomo
21 Efficacy outcomes by pathogen, including methicillin-resistant Staphylococcus aureus and the freq
22 ounds possess excellent activity against FQR methicillin-resistant Staphylococcus aureus and vancomyc
23 ia, including drug-resistant species such as methicillin-resistant Staphylococcus aureus and vancomyc
24 e Staphylococcus epidermidis and vancomycin, methicillin-resistant Staphylococcus aureus and vancomyc
25 ties against Gram-positive strains including methicillin-resistant Staphylococcus aureus and vancomyc
26 onella spp , Campylobacter jejuni/coli , and methicillin-resistant Staphylococcus aureus , and 108-14
27 ting revealed antibacterial activity against methicillin-resistant Staphylococcus aureus , and chemic
28 th various bacterial strains including MRSA (methicillin-resistant Staphylococcus aureus) and ESBL-EC
29 The risk of acquiring Clostridium difficile, methicillin-resistant Staphylococcus aureus, and multidr
30 d pneumonia/events, postprocedure pneumonia, methicillin-resistant Staphylococcus aureus, and surgica
31 beta-lactamase-producing Enterobacteriaceae, methicillin-resistant Staphylococcus aureus, and vancomy
32 were caused by group A streptococcus; 1, by methicillin-resistant Staphylococcus aureus; and 1, by S
34 activity against Listeria monocytogenes and methicillin-resistant Staphylococcus aureus at concentra
35 effectiveness with vancomycin treatment for methicillin-resistant Staphylococcus aureus bacteremia (
36 included (mean age, 59 yr); of them, 33% had methicillin-resistant Staphylococcus aureus bacteremia.
37 spitalized, adult, nondialysis patients with methicillin-resistant Staphylococcus aureus bloodstream
38 anti-staphylococcal agent due to the rise in methicillin-resistant Staphylococcus aureus, but the mec
39 the transmissibility of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) an
45 tions (SSTIs) caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) ha
48 he dramatic increase in community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in
54 ing the last 2 decades, community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) st
55 ineage of hypervirulent, community-acquired, methicillin-resistant Staphylococcus aureus (CA-MRSA) wi
56 mportant role in treating community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), r
57 target infections with community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), w
58 dren with the spread of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).
59 SA300, the most prevalent community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA).
60 vious investigations of community-associated methicillin-resistant Staphylococcus aureus(CA-MRSA) iso
61 stant bacterial clinical isolates, including methicillin-resistant Staphylococcus aureus, carbapenem-
63 We consistently observe that isolates of Methicillin-resistant Staphylococcus aureus diversify sp
64 frequency of resistant pathogens (defined as methicillin-resistant Staphylococcus aureus, Enterobacte
65 l colonization with sfb were challenged with methicillin-resistant Staphylococcus aureus in an acute
66 nces clearance of the leading human pathogen methicillin-resistant Staphylococcus aureus in vivo.
67 discrimination between unrelated strains of methicillin-resistant Staphylococcus aureus, indicating
71 e and predisposing to Clostridium difficile, methicillin-resistant Staphylococcus aureus infections a
72 nant strategy; it averted 1.31% and 1.59% of methicillin-resistant Staphylococcus aureus infections o
73 possess human efficacy for the treatment of methicillin-resistant Staphylococcus aureus infections,
74 blished IDSA guidelines for the treatment of methicillin-resistant Staphylococcus aureus infections.
75 .9%\, and were similar for 178 patients with methicillin-resistant Staphylococcus aureus isolated fro
78 igh prevalence rates of livestock-associated methicillin-resistant Staphylococcus aureus (LA-MRSA) st
79 tibiotic candidate for the treatment of both methicillin resistant Staphylococcus aureus (MRSA) and v
80 either human blood or human blood with added methicillin resistant Staphylococcus aureus (MRSA) for 9
81 f the the most dominant nosocomial bacteria, Methicillin Resistant Staphylococcus aureus (MRSA) have
86 The resistance phenotypes tested included methicillin-resistant Staphylococcus aureus (MRSA) (n =
88 ion and factors associated with clearance of methicillin-resistant Staphylococcus aureus (MRSA) after
89 as vectors for the acquisition and spread of methicillin-resistant Staphylococcus aureus (MRSA) among
90 doglycan (PG) composition in intact cells of methicillin-resistant Staphylococcus aureus (MRSA) and i
92 activity against bacterial strains including methicillin-resistant Staphylococcus aureus (MRSA) and p
93 agent, binds to the terminal peptide of the methicillin-resistant staphylococcus aureus (MRSA) and s
94 target bacterial cell wall biosynthesis, but methicillin-resistant Staphylococcus aureus (MRSA) and v
95 nt Gram-positive bacterial infections, e.g., methicillin-resistant Staphylococcus aureus (MRSA) and v
96 nces lyse bacteria including the "superbugs" methicillin-resistant Staphylococcus aureus (MRSA) and v
97 ty against the multidrug-resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and v
98 showed moderate antibiotic activity against methicillin-resistant Staphylococcus aureus (MRSA) and v
99 committee has prioritized projects involving methicillin-resistant Staphylococcus aureus (MRSA) and v
100 istance among bacterial pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and v
101 nts identified as infected or colonized with methicillin-resistant Staphylococcus aureus (MRSA) and/o
105 ug resistance and tolerance achieved amongst methicillin-resistant Staphylococcus aureus (MRSA) as we
106 imen, although there were more patients with methicillin-resistant Staphylococcus aureus (MRSA) at ba
108 hought sufficient, we present three cases of methicillin-resistant Staphylococcus aureus (MRSA) bacte
111 ycin and antistaphylococcal beta-lactams for methicillin-resistant Staphylococcus aureus (MRSA) bacte
115 rea under the curve (PAP-AUC) of consecutive methicillin-resistant Staphylococcus aureus (MRSA) blood
116 rns regarding the efficacy of daptomycin for methicillin-resistant Staphylococcus aureus (MRSA) blood
124 particular concern are globally disseminated methicillin-resistant Staphylococcus aureus (MRSA) clone
125 increases the risk of sequence type (ST) 398 methicillin-resistant Staphylococcus aureus (MRSA) colon
128 (HAP) due to gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) conti
131 al specimen collection device to be used for methicillin-resistant Staphylococcus aureus (MRSA) detec
132 nt and versatile method for the detection of methicillin-resistant staphylococcus aureus (MRSA) DNA s
133 idence also supports frequent acquisition of methicillin-resistant Staphylococcus aureus (MRSA) durin
138 Little is known about the expression of methicillin-resistant Staphylococcus aureus (MRSA) genes
139 d Kingdom MRSA database containing over 1000 methicillin-resistant Staphylococcus aureus (MRSA) genom
140 nyltransferase (MenA) was targeted to reduce methicillin-resistant Staphylococcus aureus (MRSA) growt
143 The recent spread of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) has b
147 ad infections with community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA) have
148 -infected individuals who are colonized with methicillin-resistant Staphylococcus aureus (MRSA) have
149 confirm or refute hospital/ward outbreaks of methicillin-resistant Staphylococcus aureus (MRSA) ident
150 R assays were validated for the detection of methicillin-resistant Staphylococcus aureus (MRSA) in ES
151 resis (PFGE) is a common method used to type methicillin-resistant Staphylococcus aureus (MRSA) in no
152 tive for a highly automated system to detect methicillin-resistant Staphylococcus aureus (MRSA) in pa
153 With the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) in th
155 ed States, an epidemic of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infec
156 red to vancomycin, showed higher activity in methicillin-resistant Staphylococcus aureus (MRSA) infec
158 oing dialysis are particularly vulnerable to methicillin-resistant Staphylococcus aureus (MRSA) infec
163 omycin has been the antibiotic of choice for methicillin-resistant Staphylococcus aureus (MRSA) infec
164 We report a new approach to the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infec
165 the decrease in hospitalizations related to methicillin-resistant Staphylococcus aureus (MRSA) infec
167 ive antibiotic delivery for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infec
170 Athletes are a vulnerable population for methicillin-resistant Staphylococcus aureus (MRSA) infec
172 gnificant progress has been made in reducing methicillin-resistant Staphylococcus aureus (MRSA) infec
182 Discovery of new antibiotics for combating methicillin-resistant Staphylococcus aureus (MRSA) is of
184 fection, the incidence of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) is ri
186 ic regimens in the era of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) is un
187 condition in the era of community-associated methicillin-resistant Staphylococcus aureus (MRSA) is un
188 and Etest, was prospectively assessed for 10 methicillin-resistant Staphylococcus aureus (MRSA) isola
190 molecular and microbiological evaluations of methicillin-resistant Staphylococcus aureus (MRSA) isola
191 ferral Veterinary Hospital and identified 81 methicillin-resistant Staphylococcus aureus (MRSA) isola
193 erial factors that may improve management of methicillin-resistant Staphylococcus aureus (MRSA) nosoc
194 ction control for hospital pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) often
195 ble to control the systemic dissemination of methicillin-resistant Staphylococcus aureus (MRSA) or Sa
196 ong bias for sequencing epidemic lineages of methicillin-resistant Staphylococcus aureus (MRSA) over
199 segregates positive and negative chromogenic methicillin-resistant Staphylococcus aureus (MRSA) plate
207 s Health Administration (VHA) introduced the Methicillin-Resistant Staphylococcus aureus (MRSA) Preve
208 istration of antibiotics on the detection of methicillin-resistant Staphylococcus aureus (MRSA) remai
210 rsing homes represent a unique and important methicillin-resistant Staphylococcus aureus (MRSA) reser
211 ed from patients who were undergoing routine methicillin-resistant Staphylococcus aureus (MRSA) scree
212 decolonization strategies for the control of methicillin-resistant Staphylococcus aureus (MRSA) selec
213 Effective measures are needed to prevent methicillin-resistant Staphylococcus aureus (MRSA) skin
214 Military trainees are at increased risk for methicillin-resistant Staphylococcus aureus (MRSA) skin
215 ety of Anesthesiologists score, preoperative methicillin-resistant Staphylococcus aureus (MRSA) statu
216 e activation of proinflammatory signaling by methicillin-resistant Staphylococcus aureus (MRSA) strai
217 f last resort; however, clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) strai
218 anges that accompany selection of mutants of methicillin-resistant Staphylococcus aureus (MRSA) strai
219 vancomycin MIC values of </=1 to >/=2 in 200 methicillin-resistant Staphylococcus aureus (MRSA) strai
221 otypically defined community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA) strai
222 te of choice for the Veterans Administration methicillin-resistant Staphylococcus aureus (MRSA) surve
223 odstream infections and clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) than
224 bloodstream infection caused by a strain of methicillin-resistant Staphylococcus aureus (MRSA) that
225 macrolide/lincosamide usage on resistance of methicillin-resistant Staphylococcus aureus (MRSA) to ci
226 gnificant reduction in the production of key methicillin-resistant Staphylococcus aureus (MRSA) toxin
229 global regulator sarA modulates virulence of methicillin-resistant Staphylococcus aureus (MRSA) via r
231 es completed batched PCR; results other than methicillin-resistant Staphylococcus aureus (MRSA) were
232 ing) as a DNA biosensor for the detection of methicillin-resistant Staphylococcus aureus (MRSA) which
233 ndemic multi-resistant healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) with
234 erformance of BD Max StaphSR and the rate of methicillin-resistant Staphylococcus aureus (MRSA) with
235 last resort for serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA)(1,2).
236 y against important Gram-positive (including methicillin-resistant Staphylococcus aureus (MRSA)) and
238 e prevalence rates of Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA), and
239 0 patient-days) of nosocomial BSIs caused by methicillin-resistant Staphylococcus aureus (MRSA), ARB
240 l site infections (SSIs), commonly caused by methicillin-resistant Staphylococcus aureus (MRSA), are
241 ta-lactam antibiotics in multidrug-resistant methicillin-resistant Staphylococcus aureus (MRSA), but
242 ic distribution of different clonal types of methicillin-resistant Staphylococcus aureus (MRSA), few
244 am antibiotic for treatment of infections by methicillin-resistant Staphylococcus aureus (MRSA), is a
245 esistance, particularly in pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), limi
246 in-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), List
247 l blood or respiratory cultures positive for methicillin-resistant Staphylococcus aureus (MRSA), Pseu
248 inst various drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), vanc
249 stence of, and time to new colonization with methicillin-resistant Staphylococcus aureus (MRSA), vanc
250 n metagenome sequencing for the detection of methicillin-resistant Staphylococcus aureus (MRSA), vanc
251 antigen that contributes to the virulence of methicillin-resistant Staphylococcus aureus (MRSA), whic
252 er daptomycin doses are advocated for select methicillin-resistant Staphylococcus aureus (MRSA)-relat
253 ) as an antibiotic effective in vivo against methicillin-resistant Staphylococcus aureus (MRSA).
255 bacter cloacae, Acinetobacter baumannii, and methicillin-resistant Staphylococcus aureus (MRSA).
256 ists also at the allosteric site of PBP2a of methicillin-resistant Staphylococcus aureus (MRSA).
257 des for the treatment of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).
259 e therapies in invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
260 coccal and staphylococcal bacteria including methicillin-resistant Staphylococcus aureus (MRSA).
261 onia and other invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
263 ted infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA).
264 resistance to the beta-lactam antibiotics by methicillin-resistant Staphylococcus aureus (MRSA).
265 r documenting clearance of colonization with methicillin-resistant Staphylococcus aureus (MRSA).
267 st beta-lactams, leading to the phenotype of methicillin-resistant Staphylococcus aureus (MRSA).
269 d exhibit potent antibiotic activity against methicillin-resistant Staphylococcus aureus (MRSA).
270 own what factors account for transmission of methicillin-resistant Staphylococcus aureus (MRSA).
271 abscess have increased with the emergence of methicillin-resistant Staphylococcus aureus (MRSA).
272 (1) have been synthesized and tested against methicillin-resistant Staphylococcus aureus (MRSA).
273 mycin-resistant Enterococcus faecium (n=19), methicillin-resistant Staphylococcus aureus (n=17), and
274 ent visits were only significantly higher in methicillin-resistant Staphylococcus aureus (OR, 2.80; 9
275 on, or infection with Clostridium difficile, methicillin-resistant Staphylococcus aureus, or vancomyc
276 monstrate the utility of SVAMP in tracking a methicillin-resistant Staphylococcus aureus outbreak fro
277 d, with a particular focus on vancomycin for methicillin-resistant Staphylococcus aureus, penicillin
278 20) followed by Candida species (PNNT = 34), methicillin-resistant Staphylococcus aureus (PNNT = 38),
279 m was to estimate costs and effectiveness of methicillin-resistant Staphylococcus aureus prevention p
280 e A, a spirotetronate that is active against methicillin-resistant Staphylococcus aureus, rapidly col
283 recombinase, limits biofilm formation in the methicillin-resistant Staphylococcus aureus strain LAC a
284 epidemiology of a novel livestock-associated methicillin-resistant Staphylococcus aureus strain, whic
286 aloid library, that selectively resensitizes methicillin-resistant Staphylococcus aureus strains to b
288 how that during a bloodstream infection with methicillin-resistant Staphylococcus aureus, the majorit
289 ive cohort study of 1,140 patients harboring methicillin-resistant Staphylococcus aureus, the nasal b
291 tions with the epidemic community-associated methicillin-resistant Staphylococcus aureus USA300 is to
293 nst common gram-positive pathogens including methicillin-resistant Staphylococcus aureus, vancomycin-
294 Gram-negative) and drug-resistant bacteria (methicillin-resistant Staphylococcus aureus, vancomycin-
295 scherichia coli, Salmonella typhimurium, and methicillin-resistant Staphylococcus aureus) were succes
296 red according to type of pathogen, including methicillin-resistant Staphylococcus aureus, were simila
297 pacia J2315, Mycobacterium tuberculosis, and methicillin-resistant Staphylococcus aureus, whereas AGS
298 to 15%, with an alarming frequency caused by methicillin-resistant Staphylococcus aureus, which is pr
299 es against Gram-positive pathogens including methicillin resistant Staphylococcus aureus with minimum
300 ration of 10(7) CFU/mL and 95.4 +/- 1.0% of Methicillin-resistant Staphylococcus aureus with startin
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。